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INTRODUCTION 
 Diabetes mellitus as we all know is a systemic disorder which 
affects many organs by causing pathological changes in them. It is 
considered as a leading  cause of increasing  morbidity and deaths in 
todays world. 
 Many theories have been suggested to explain the end organ 
damage induced by hyperglycaemia. These are : 
1 
                    1.Formation of advanced glycosylation end products  
                    2.Glucose metabolism via sorbitol pathway 
                    3.Activation of protein kinase C and 
                   4.Increase in flux via hexosamine pathway. 
 These processes  plays the main role in causing impairement of 
collagen & elastin cross linkage, which therby causes reduced elasticity 
of connective tissue 
2,3 
. As per the epidemiological survey, the 
prevelance of diabetes mellitus is projected to be highest by 2025 in asian 
Indians 
4
. 
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 The vascular complications of  DM remains the main cause of 
mortality & morbidity. It includes macrovascular and  microvascular ie.., 
retinopathy, neuropathy and nephropathy. Generally the microvascular 
complications occur early in the course of diabetes ie.., 5 to 10 years and 
it takes 10 to 15 years for macrovascular complications to develop
5
. 
Eventhough respiratory tract infections like tuberculosis is increased in 
incidence in patients with diabetes mellitus, attention is only minimally 
given to respiratory system.                         
 This study is aimed to detect the abnormalities in pulmonary 
functions in Type 2 DM patients. The presence of abundant connective 
tissue and microvascular circulation in lung raises the possibility that in 
diabetic patients, lung could also be a “target organ”.Chronic 
hyperglycaemia  causes many histopathological changes in the lungs of 
diabetics. These are thickening of alveolar epithelium and the basal 
lamina of pulmonary capillaries. These changes ultimately results in 
reduction in elastic recoiling capacity and the lung volume. The reason 
would probably be the non-enzymatic glcosylation induced connective 
tissue alteration in lung parenchyma. 
6 
 The literature tells us that only very few studies have been carried 
out to explain the pathological effects of diabetes mellitus on pulmonary 
functions. So this study would add more to the growing literature on 
pulmonary functions in patients with diabetes mellitus.  
 12 
 
AIM OF THE STUDY 
 
1.  To record the  Pulmonary function tests  in Type 2 
DM group as well as in the control group. 
 
2.  To compare the pulmonary functions between  the  2 groups. 
 
3.  To analyse the pulmonary functions in Type 2 DM 
patients with respect to the duration of diabetes and their 
recorded blood sugar values.     
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REVIEW OF LITERATURE 
INTRODUCTION : 
 The group of metabolic disorders which share the phenotype of 
hyperglycaemia is referred as DIABETES MELLITUS. Complex 
interaction of various factors including environmental & genetic is the 
cause for several distinct types diabetes mellitus. 
 The factors contributing to hyperglycaemia are decrease in insulin 
secretion, decrease in utilization of glucose, and increase in glucose 
production. This dysregulation  causes secondary changes in various 
organ systems and imposing burden on the person with diabetes and also 
on the health care system.
7 
EPIDEMIOLOGY: 
 The international diabetes federation according to current trends 
projects that 438 people will have diabetes by the end of year 2030. The 
rising prevelance of Type 2 DM is more rapid because of sedentary life 
style, increasing obesity and the aging of population. Geographic 
variation has a considerable role in the incidence of Type 1 & 2 DM.
7 
 14 
 
The prevelance of Type 2 DM in asia is increasing rapidly and 
more importantly, the diabetes phenotype appears to be different from the 
united states – onset at a lower BMI, greater visceral adiposity, younger 
age and decreased capacity of insulin secretion
7
. People of south asia 
have a very high rate of diabetes and they too have highest rates of 
premature CVD ( cardiovascular disease ). in the world
8
. 
 India, china  along with middle east countries are now the  'hot 
spots' according to diabetes data, since the incidence of disease in next 20 
years is likely to double
9
.  A rough estimation of prevelance of diabetes is 
about 12% in india and it is expected to increase in next coming years
10
. 
 According to data from International diabetes federation,   
4.6 million people of the age group 20-79 years died in 2011 due to 
diabetes. This number equals the magnitude of combined deaths from 
various major infectious diseases. Highest numbers being from india, 
china & united states of america
11
. 
 There is 13.3% increase in number of deaths related to diabetes in 
2011 compared to the estimated deaths of year 2010
12,13
.   
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DIAGNOSIS
7
 :                                    
 
Symptoms of diabetes include :  
 Fatigue  
 polyuria 
 polydypsia 
 polyphagia 
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CLASSIFICATION 
7
 : 
 
Abbreviation : MODY – Maturity onset ‘diabetes of  the young’ 
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INSULIN : BIOSYNTHESIS, SECRETION AND ACTION 
BIOSYNTHESIS:  
 The beta cells of the islets of pancreas produces insulin. The 
preproinsulin is the initial component which is synthesized as a precursor 
polypeptide having single chain 86- amino acid. Thereafter undergoes 
proteolysis to give rise to proinsulin, which is related to IGF 1 & 2 
structurally. Further cleavage from proinsulin gives rise to A & B chains 
of insulin and the C peptide. The beta cells store them together & in 
secretory granules which are then co secreted
7
. 
 
 
Figure 1 . showing PROINSULIN ( A & B chain of mature insulin  
along with C peptide ) 
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SECRETION:  
 Insulin secretion by beta cells of pancreas is influenced by many 
factors like, amino acids, nutrients, ketones, and gastrointestinal peptides. 
The most important key regulator being glucose. Insulin synthesis is 
stimulated when glucose levels are above 70mg/dl and primarily due to 
the enhancement of protein translation and its processing. The rate 
limiting step which controls the insulin secretion related to glucose 
regulation is glucokinase mediated glucose phosphorylation. Insulin 
secretion is stimulated when voltage gated calcium channels open due to 
depolarization of beta cell membrane induced by potassium channel 
inhibition
7
. 
 
Figure 2. showing mechanism of secretion of insulin. 
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 GLUT-2 mediates intracellular transport of glucose. glucose 
undergoes oxidation to yield  ATP  which inhibits potassium channel 
receptor on B cell. thereby causing  membrane depolarisation, Ca
2
  ion 
influx   followed by release of stored insulin. 
 Gastrointestinal tract also plays a role by releasing incretins from 
the neuroendocrine cells when food is ingested and thereby amplifies 
insulin secretion and  suppresses secretion of glucagon. The L- cells of 
the small intestine release GLP-1 which stimulates secretion usually 
when blood glucose is more than the fasting level. 
ACTION:  
 Once insulin secretion occurs into the portal venous system, about 
50% is immediately removed and undergoes degradation in liver. The 
remaining enters systemic circulation to bind to target receptors. The 
receptors gets autophosphorylated along with recruitment of signalling 
molecules such as IRS i.e., insulin receptor substrates. IRS along with 
some adaptor proteins initiates a cascade resulting in reaction of 
phosphorylation & dephosphorylation causing metabolic effects of 
insulin. Other pathways related to insulin receptor signalling also gets 
activated to induce glycogen synthesis, lipogenesis and protein synthesis
7
. 
 20 
Figure 3. Metabolic  pathway  showing  fuel  metabolism  & insulin  
actions 
14
: 
 
 
( + ) ------> stimulation by insulin 
( - ) -------> inhibition by insulin  
FFA ------> Free fatty acids 
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BLOOD GLUCOSE REGULATION : 
 Blood glucose regulation is very important for the survival of 
human beings. Glucose level has to be finely regulated so as to supply 
glucose to brain which does not have the capacity to store glucose. 
Glucose also acts as fuel for kidney and RBCs. 
 
  
 
 
 
 
 
 
 
 Figure 4.  showing glucose metabolism( Glycogenolysis & Glycolysis ) 
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 Dietary carbohydrates are finally converted to glucose.
15
 Dietary or 
cellulose protein catabolism results in carbon atoms which are used in 
glucose synthesis, a process  called gluconeogenesis. Tissues other than 
liver which oxidise glucose incompletely provide lactate which can be 
converted to glucose through gluconeogenesis
15
.  
 Liver is the predominant organ which responds to fluctuation in 
blood sugar levels. Synthesis of glucose is on one of the important 
functions of the liver.  Increased or decreased glucose levels trigger 
several hormonal mechanism that helps to restore normal glucose levels. 
Whenever there is low blood sugars level, pancreatic a cells are 
stimulated and glucagon is released
16
. When sugar level is high Beta cells 
of pancreas are stimulated and insulin is released into the circulation. 
Pituitary hormones, GH, ACTH inhibit glucose uptake by extrahepatic 
tissues and thus act to increase blood glucose. Glucocorticoids also 
inhibit glucose uptake and increased blood glucose levels. Circulating 
ACTH stimulates adrenal cortex to release cortisol which increases 
glucose levels in blood. Adrenal medullary hormone, epinephrine which 
is secreted when there is any stressful event, activates glycogenolysis and 
increase blood sugar levels
16
.  
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 When blood glucose levels are low, there is no uptake of glucose 
by the liver. Conversely when there is high blood glucose, there will be 
increased blood glucose uptake by the liver and conversion of glucose to 
glycogen, stored for future needs. 
 Whenever there is high blood glucose, there will be high liver 
glucose. Under such conditions glucokinase activity is increased G6P is 
rapidly converted to GIP by the enzyme, phosphoglucomutase, which is 
then incorporated into glycogen
15
.  
METABOLISM OF GLUCOSE IN DM2:  
 There will be increased glucose output by liver in DM. First, 
glycogen is utilized to produce glucose. Next gluconeogenesis takes 
place. Insulin deficiency causes impairment of glucose utilization by non 
hepatic tissues. Mainly skeletal muscle and fatty tissue are insulin 
dependent tissues. Reduced utilization of glucose by peripheral tissue 
leads to decreased rate of glucose metabolism. As insulin regulates the 
activity of hepatic glucokinase, there will be decreased rate of 
phosphorylation of glucose in liver cells leading to increased transport to 
blood
16
. Combined effect of increased glucose synthesis and reduced 
utilization leads to elevated plasma sugar values. When renal capacity of 
sugar handling is overcome by hyperglycemia there will be glucosuria. 
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Glucose acts as an osmotic diuretic and its loss is accompanied by water 
and electrolyte loss causing polyuria. Polyuria stimulates thirst 
mechanism causing polydipsia
16
. Glycosuria, tissue catabolism and 
impairment of hypopthalamic regulation cause increased appetite and 
intake of food (Polyphagia)
16
.  
TYPE 2 DIABETES MELLITUS:  
 Type 2 DM is characterised by insulin resistance and deficient 
insulin secretion. The primary defect is still controversial. This systemic 
disorder has a very strong genetic component
7
. 
TABLE 3 : GLUCOSE HOMEOSTASIS
7 
 
Abbreviations: FPG - Fasting Plasma Glucose 
  2h PG - 2 hrs Post prandial Glucose 
  HBA1c- Glycosylated hemoglobin 
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RISK FACTORS FOR TYPE 2 DM 
7
: 
1. Family h/o DM 
2. Obesity ( body mass index > 25 Kg/m2) 
3. Race or ethnicity  
a. African American 
b. Native American 
c. Asian American 
d. Latin 
4. Presence of impaired fasting glucose, impaired glucose tolerance or 
HbA1c of 5.7 – 6.4% 
5. Systemic hypertension ( BP > 140 mm of Hg ) 
6. HDL cholesterol < 35 mg/dl 
7. Triglycerides > 250 mg/dl 
8. Polycystic ovarian syndrome or acanthosis nigricans 
9. History of cardiovascular disease. 
PATHOPHYSIOLOGY:  
 Impaired insulin secretion, insulin resistance, increased glucose 
production from liver, and abnormal fat metabolism are the main 
characteristics  of Type 2 DM. Obesity (central or visceral) is strongly 
associated with Type 2 DM
7
.  
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 Initially the beta cells compensate for the insulin resistance in the 
early stages by increasing insulin output. As this progresses, the beta cells 
fail to sustain the hyperinsulinemic state. Impaired glucose tolerance 
develops i.e., elevation in post prandial glucose. Later occurs fasting 
hyperglycemia due to decline in secretion of insulin and increase in 
glucose production by liver. Finally there ensues beta cell failure
7
. 
COMPLICATIONS OF TYPE 2 DIABETES MELLITUS :  
ACUTE COMPLICATIONS: 
 Diabetic keto acidosis : it results from insulin deficiency which 
may    be relative or absuolute, in combination with excess amount 
of counter regulatory hormones like cortisol, glucagon, 
catecholamines, and growth hormone. There occurs promotion of 
glycogenolysis, gluconeogenesis along with ketone body 
formation
7
. 
 
 Hyperglycemia, ketosis  along with metabolic acidosis  and 
secondary metabolic derangements in the form of  reduction of body 
stores of  sodium, chloride, phosphorous and  magnesium. Blood urea and 
serum creatinine also gets elevated. 
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 Hyperglycaemic  hyperosmolar  state : this usually occurs in an 
elderly patient with Type 2 DM  with history of polyuria and 
weight loss for several weeks. The  patient finally ends up in 
mental confusion and lethargy, or coma.
7 
Acute
 
myocardial 
infarction and Acute cerebrovascular accident being the common 
cause which precipitates it.  
 
 Marked hyperglycemia ( >1000 mg/dl ) 
 Hyper osmolality ( >350 mosmol/L ) 
 Pre renal azotemia,  
 Ketonemia 
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Symptoms and signs explaining the pathophysiological basis in the 
uncontrolled Diabetes mellitus
Lack of Insulin
Decreased anabolism
Increased secretion 
of Glucagon
Cortisol
Growth Hormone
Catecholamines
Increased catabolism
Hyperglycemia
Glycosuria
Osmotic 
diuresis
Fatigue
Vulvitis
Balanitis
Polyuria
Polydypsia
Glycogenolysis
Gluconeogenesis
Lipolysis
Hyperketonaemia
Acidosis
Hyperventilation 
&
Peripheral 
Vasodilatation
Hypotension
&
Hypothermia
Diabetic 
ketoacidosis
Death
Salt and water 
depletion
Tachycardia
Hypotension
Wasting
Loss of 
weight
 
Figure 5. pathophysiological basis for uncontrolled diabetes mellitus. 
CHRONIC COMPLICATIONS
7
 : 
MICROVASCULAR : 
1. Eyes – retinopathy ( non proliferative/proliferative), macular edema 
2. Nerves – neuropathy ( sensory/motor, autonomic ) 
3. Kidneys – nephropathy 
MACROVASCULAR : 
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1. Coronary heart disease 
2. Cerebrovascular disease 
3. Peripheral arterial disease 
OTHERS : 
1. Gastroparesis, diarrhea 
2. Sexual dysfunction/ uropathy 
3. Dermatological 
4. Infections 
5. Cataract  
6. Glaucoma 
7. Periodontal disease 
8. Hearing loss 
MECHANISM OF COMPLICATIONS : 
 There are atleast four theories, which can explain the chronic 
complications induced by hyperglycemia. 
 One theory states that increase in intracellular glucose will lead to 
AGEs formation, which binds to cell surface receptor. The interaction 
between  glucose and aminogroups on proteins results in non-enzymatic 
glycosylations. These AGEs can cross link proteins, induce accelerated 
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atherosclerosis, decrease synthesis of nitric oxide. It also causes 
endothelial & glomerular dysfunction and alters the extracellular matrix 
structure & its composition
7
. 
 The second theory states that hyperglycemia in increase glucose 
metabolism via a special pathway called sorbitol pathway. Metabolism of 
intracellular glucose predominantly takes place by phosphorylation and 
glycolysis subsequently. When glucose level increases, some is converted 
to sorbitol by the action of enzyme aldose reductase. Increase in sorbitol 
concentration can alter the redox potential therby increasing cellular 
osmolality, generating reactive oxygen species
7
. 
 The third one states that hyperglycemia activates protein kinase C. 
This can alter the gene transcription for fibronectin, contractile proteins, 
type 4 collagen and matrix protein in endothelial cells and neurons
7
. 
 The fourth theory states that there occurs an increase in flux via 
hexosamine pathway induced by hyperglycemia. It causes function 
alteration by protein glycosylation or by changing gene expression of 
TGF  beta ie.., transforming growth factor- B or PAI-1 ie.., plasminogen 
activator inhibitor-1.
(7) 
GLYCEMIC CONTROL : 
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 The famous DCCT ie.., diabetes control and complications trial 
was a land mark study which emphasised on the concept that prompt 
control of chronic hyperglycemia would prevent many complications in 
case of  type1 DM. More than 1400 members were randomized to either 
conventional diabetes management or intensive management. They were 
evaluated prospectively for the development of retinopathy, neuropathy 
or nephropathy.
( 17,18,19,20 ) 
 
This study demonstrated that intensive glycemic control can slow 
down the progression of early complications in diabetes mellitus. 
Intensive treatment was in the form of multiple administrations of insulin 
each day along with educational & medical support. Conventional being 
twice daily insulin injections and quartenary clinical evaluation. 
(19,20 ) 
Results were:  1.  Reduction in NPDR & PDR by 47% 
   2. Reduction in microalbuminuria by 39% 
   3. Reduction in clinical nephropathy by 54% & 
  neuropathy by 60%.   
 
 The UKPDS ie.., United Kingdom Prospective Diabetes Study 
covered > 5000 individuals with history of Type 2 DM for > 10 years. 
 32 
Multiple treatment regimens were utilized for this randomized study ie.., 
one group with insulin & oral hypoglycaemic agents( sulfonylurea or 
metformin) and the other group were given conventional 
pharmacotherapy just to prevent symptoms.
21 
 HbA1c of 7% was achieved with intensive treatment arm and 7.9% 
was in the standard treatment arm. Conclusion was for each percentage 
reduction in HbA1c there was 35% reduction in microvascular 
complications.
21,22,23 
 Kumamoto study was a small trial study on japanesee with Type2 
DM who were lean individuals. Results were reduction in risks of 
microvascular complications in them. These studies finally gives is an 
idea about the value of metabolic control in view of reducing the 
complications
24
. 
OPHTHALMOLOGIC COMPLICATIONS OF TYPE 2DM:  
 There are 2 stages of diabetic retinopathy : Non proliferative & 
proliferative. NPDR is characterised by vascular micro aneurysms, cotton 
wool spots and blot haemorrhages. The pathophysiology behind is the 
loss of retinal pericytes, increase in permeability of the retinal 
 33 
vasculatures, retinal blood flow alteration. These finally lead to retinal 
ischaemia
14
. 
 Progressing retinal hypoxemia causes neovascularisation which is 
the hallmark of PDR. These new vessels appearing very near to optic 
nerve or/and macula can rupture easily causing vitreous haemorrhage and 
ultimately lading to retinal detachment. If NPDR is severe, it can evolve 
into PDR within 5 years. Macula edema is clinically significant oly when 
NPDR is present. Macula edema can be detected by fluorescien 
angiography. Thereafter moderate visual loss will ensue in few years
14
.                                       
Clinical features 
14
: 
1. MICROANEURYSMS : this is the earliest detected abnormality in 
most cases. These are tiny and discrete looking circular red dots near 
to the vessels in retina. These microaneurysms look like 
haemorrhagic spots and they arise from the venous end of capillaries. 
 
2. HAEMORRHAGES : These are round & regular shaped which occur 
in deeper layers of retina and are called as blot haemorrhages 
3. EXUDATES : These are usually seen in the perimacular area with 
varying size. They also appear as large confluent patches. These are 
due to leakage of plasma from retinal capillaries which are abnormal. 
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4. COTTON WOOL SPOTS : seen in rapidly progressing retinopathy 
due to arterial occlusions leading to retinal ischaemia.  
 
5. VENOUS CHANGES : venous dilatation is an early abnormality due 
to increase in blood flow. Increased tortuosity and beading represents 
severe form of pre-proliferative retinopathy. 
 
6. NEOVASCULARISATION : New vessels are formed in response to 
wide spread ischaemia. They arise from the venous circulation 
forming arcades of tufts of vessels on the retinal surface. They can 
easily rupture and can cause pre retinal or vitreous haemorrhage. In 
severe cases causes sudden visual loss. 
 
7. RUBEOSIS IRIDIS : these are new vessels forming on the anterior 
surface of iris. Its a sign of proliferative retinopathy. Obstruction at 
the angle of eye can cause secondary glaucoma. 
 
 
Figure 6 : Fundus picture of diabetic retinopathy 
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DIABETIC NEPHROPATHY : 
 Diabetic retinopathy is a leading cause of morbidity and mortality 
related to diabetes mellitus. The risk of cardiovascular disease also 
increases in the presence of  micro or macroalbuminuria. It is commonly 
associated with diabetic retinopathy
7,37
. 
           Chronic hyperglycemia leading to ESRD involves
7,38
 :  
 Effects of soluble factors like AGEs, 
angiotensin 2, endothelin and growth factors. 
 Glomerular hyperfiltration by change in renal 
microcirculation. 
 Change in glomerular structure 
 Basement membrane thickening 
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 Mesangial expansion  & fibrosis.  
 Some of the effects are mediated through angiotensin 2 receptors. 
The main risk factors is positive family history of diabetes nephropathy.  
Smoking also causes decline in renal function. The sequential events 
which are predictable in the natural history of diabetic nephropathy  in 
Type 2 DM appears to be similar to that of Type 1 DM
7
.  
 During the first years after the onset of diabetes , for example in 
Type 1 DM  there occurs  an increase in glomerular filtration rate due 
glomerular hyperperfusion. Over the first 5 years successive changes 
occur such as glomerular basement membrane thickening along with 
hypertrophy. Also there occurs expansion of the mesangium. After 5 to 
10 years, microalbuminuria sets in and progresses to macroalbuminuria. 
This proceeds to ESRD in 7 o 10 years 
7
. 
 The nephropathy which develops in patients wih Type 2 DM 
differs from Type 1 in the following ways
7
 :  
1. Albuminuria ( micro or macro ) may be present when the 
diagnosis of Type 2 DM is made. 
2. Albuminuria is often accompanied with hypertension. 
3. Microalbuminuria cannot always predict nephropathy. 
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4. Heart failure, hypertension , infections can also cause 
microalbuminuria which are actually secondary causes. 
SCREENING FOR MICROALBUMINURIA: 
 It should be detected at an early stage when therapies can be 
institueted effectively. Microalbuminuria is an cardiovascular risk factor.  
Prompt glycemic control can reduce the rate of urine albumin excretion.  
 The effective interventions for preventing the progression of 
microalbuminuria to macroalbuminuria are
7
: 
1. Glycemic control to normal levels. 
2. Very strict control of blood pressure. 
3. Starting treatment  with ACE inhibitors or ARBs 
4. Correction of  dyslipidemia. 
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Figure 7.  SCREENING FOR MICROALBUMINURIA 
 
   
 
 
 
 
 
 
 
 
 
 
DIABETIC NEUROPATHY  
 The prevelance of DM in india is 4.3%
25
, whereas in west its 
around 1 – 2%26. The reason may be the insulin resistance which is more 
pronounced in asian Indians
27
. A recent study done in south india 
revealed 19.1% incidence rate of peripheral neuropathy in Type 2 DM
28
. 
it is one of the most commonest causes of peripheral neuropathy. 
Autonomic neuropathy due to diabetes causes death in 25%-50% within a 
period  of  5-10 years
29,30
. In an another study, an increase in incidence of 
Spot microalbumin test 
Exclude other causes for 
albumin excretion 
Repeat test in 3 to 6 
month period 
2 out of 3 tests +ve Start treatment 
-- 
 
yes no 
Annually 
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neuropathy from 7.5%  to  50% at 25 years follow up has been 
documented
31
. 
CLINICAL CLASSIFICATION OF DIABETIC NEUROPATHY
32
 : 
SYMMETRIC :  
1. Polyneuropathy 
2. Painful autonomic neuropathy 
3. Painful distal neuropathy with loss of weight known as “diabetic 
cachexia” 
4. Insulin neuritis 
5. Polyneuropathy after DKA 
6. CIDP with diabetes mellitus 
 
ASYMMETRIC : 
1. Radiculoplexoneuropathies ( lumbosacral, thoracic, cervical ) 
2. Mononeuropathies 
3. Median neuropthy ( wrist ) 
4. Ulnar neuropathy (elbow ) 
5. Peroneal neuropathy ( fibular head )             
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Figure 8. showing various presentations of diabetic neuropathy 
A. Distal symmetrical polyneuropathy 
B. Proximal neuropathy 
C. Cranial neuropathy 
D. Mononeuropathy multiplex  
Various clinical features of diabetic autonomic neuropathy are : 
 resting tachycardia 
 orthostatic hypotension 
 bladder emptying abnormalities 
 sympathetic nervous system dysfunction ( hyperhidrosis, 
anhidrosis ) 
 hypoglycemic unawareness. 
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PATHOGENESIS OF DIABETIC NEUROPATHY :     
 Hyperglycemia causes increased endothelial vascular resistance 
and reduce the nerve blood flow. It also decreases the level of 
myoinositol in nerve fibres. Accumulation of fructose and sorbitol in 
nerve leads to non-enzymatic glycosylation of nerve proteins. Protein 
kinase C activation also plays a major role in vascular damage to nerve 
resulting in defective axonal transport
7
. 
DIAGNOSIS :  
 It includes assessment of power of muscle, assessment of posterior 
column and temperature sensations. Tuning fork of 128 Hz is used for 
testing vibration sense and microfilament of 1 gm for testing touch 
sensation
33
. The tests based on blood pressure and heart rate response to 
specific manoeuvres are used to assess autonomic functions. Nerve 
biopsy is useful just to exclude other causes  of neuropathy
34
. 
 The American academy of neurology has recommended  that DN 
should be diagnosed in the presence of sensory or autonomic neuropathy 
only after excluding other causes
35
. The nerve conduction velocity is 
diminished gradually in DN, with an estimated loss of about 
0.5/sec/year
36
.      
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CARDIOVASCULAR MORBIDITY AND MORTALITY 
 The very famous FRAMINGHAM HEART STUDY concluded 
saying increase in the incidence of heart failure, coronary heart disease, 
peripheral arterial disease and sudden death in  diabetes patients. DM has 
been considered as “CHD  risk  equivalent” by American heart 
association. Synergism of increased glucose level with other cardiac risk 
factor, is the likely the cause of increase in cardiovascular morbidity and 
mortality rates. The other risk factors include hypertension, obesity, 
dyslipidemia, physical inactivity, and smoking. Type 2 DM patients have 
increased levels of PAI-1 (plasminogen activator inhibitor-1) & 
fibrinogen, which impairs fibrinolysis and enhance the coagulation 
process
7
. 
GASTROINTESTINAL AND GENITOURINARY DYSFUNCTION  
 Gastroparesis and bowel motility alteration are the most common 
GI symptoms in patients with diabetes mellitus. Symptoms of 
gastroparesis include nausea, vomiting, abdominal bloating, early satiety. 
Chronic hyperglycemia causes dysfunction of parasympathetic nervous 
system and can impair gastric emptying. Normal diarrhea is a feature of 
GI autonomic neuropathy related to diabetes
7
.  
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 The genitourinary abnormalities includes, erectile dysfunction, 
decreased sexual desire, decreased vaginal lubrication, dyspareunia.            
Diabetic  cystopathy is defined as inability to sense the fullness of bladder 
& difficulty to void urine comple ely. Later progresses to symptoms like 
urinary hesitancy and  incontinence
7
. 
INFECTIONS  
 Diabetic patients have increased frequency and severity of 
infections. The factors responsible include, defective cell mediated 
immunity & phagocyte dysfunction due to hyperglycemia, along with 
decreased vascularization. Some rare infections like rhinocerebral 
mucormycosis, emphysematous pyelonephritis & gall bladder, malignant 
otitis externa are excluding seen in Type 2 DM
7
. 
 As far as pneumonia is considered gram negative organism like 
mycobacterium tuberculosis, staphylococcus aureus are more frequent 
pathological agents. Escherichia coli is the most common pathogen 
associated with pyelonephritis in diabetes. DM patients are more to 
colonization of staph.aureus in the skinfold and nares
7
. 
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DERMATOLOGICAL MANIFESTATIONS 
 Defective wound healing and ulcerations of skin are common skin 
manifestations of DM. The pigmented pretibial papules starts with an 
area of  erythema and evolving into circular hyperpigmentation. These 
results from minor trauma in the pretibial region.
7 
 The other specific skin disorders includes
7 
a. Bullosa diabeticorum 
b. Necrobiosis lipoidicum diabeticorum 
c. Granuloma annularae  
d. Sclerederma. 
EFFECT OF DIABETES ON RESPIRATORY SYSTEM:  
 Integrity of connective tissue of the lung and microvasculature of 
the lung influence the normal mechanics and gas exchange. Diabetes 
effects either of these two structural components leading to pulmonary 
function abnormality, like decreased vital capacity, compliance of the 
lung, TLC, decreased central and peripheral airflows, rapidity of aging 
process, thickening of capillary endothelial basement membrane and 
alveoli, modification of surfactant and its function, pulmonary 
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microangiopathy which leads to decreased diffusing capacity and 
endurance of respiratory musculature.  
Figure 9. showing alveolar structure 
 
PULMONARY FUNCTION TEST: 
 Gas exchange remains the most essential fuction of lung, occurring 
at the alveolar level. ie., between the air in the alveoli and the blood 
present in the alveolar capillaries. Due to the gas transfer the pressure is 
maintained for oxygen at 100mm of Hg and for carbondioxide its around  
40mm of Hg. This is achieved through various mechanisms like 
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ventillation, diffusion, oxygen transport and its utilisation. Lungs also 
play a vital role in maintaining the acid base balance in our body
39
.  
Figure 10 . showing the bronchopulmonary  tree with its vasculature 
 
Assessment of pulmonary functions has a wide range of applications
39
 : 
1. Characterising the type of dysfunction to aid diagnosis 
2. Preoperative evaluation 
3. Assessment of disease progression 
4. Monitoring response to therapy 
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 Spirometer is a simple instrument  which is used to diagnose and 
manage patients with pulmonary disorders. The interpretation is 
challenging as it is mainly dependent on patients effort  and the 
interpreter's knowledge  about the reference values as per  age, sex and 
weight. A stepwise method is recommended. Determining the validity of 
the test  should be the first step. Next  being  the determination of 
ventillatory pattern ie., normal, obstructive or restrictive
39
. 
TABLE 4. showing spirometric parameters 
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Spirometry Measurements  
 Spirometry records and measures the rate of lung volume changes 
during  forcefull breathing. It begins with a full inhalation, followed by 
rapid emptying of the lungs by forced exhalation, continuing till a plateau 
in exhaled volume is attained. These efforts are finally  recorded and 
graphed. 
 The most important spirometric data is the FVC, the patient inhales 
maximally, followed by exhaling completely as possible. Normally lungs  
can empty > 80 percent of their volume in 6 secs or less. The FEV1  is the 
volume of air which is exhaled in the 1st second of the FVC maneuver. 
The FEV1/FVC ratio is generally expressed as a percentage. For 
interpretation,the absolute value is used and  not the percent predicted
39
. 
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figure 11. normal spirometric flow curve  
 
 
 
 
 
 
 
 
. 
 
 
Diagram showing normal spirometric flow 
 
 
(A) Flow-volume curve  
(B) Volume-time curve extending 
more than 6 seconds. 
 
 50 
Figure 12. patterns of spirometric curves 
 
Interpreting Spirometry Results 
 Before interpretation , the results must be assessed for validity.
40,41
 
often there occurs misdiagnosis because of inadequate patients effort. The 
normal spirometry values vary with respect to patient's age, height, 
weight, sex, and ethnic background
42,43
. Predicted values may be 
inaccurate in very tall individuals or persons with absent lower 
extremities. FEV1 and FVC are lesser in blacks and Asians compared to 
whites. FVC can vary with the change of position. FVC is about 2 percent 
greater in standing position compared to supine. 
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 At least 3 acceptable spirograms should be obtained to determine 
the validity of results. Every time, patient should exhale for at least 6 secs 
and stop when no volume change occurs  for 1 second. The session is 
over when the difference between  2  largest FVC values and between the 
2 largest FEV1 values is within 0.2 L. If both these are not met even after 
three times, interpretation is not recommended. Tests should be repeated 
till  the criteria are met
44
. 
 When there is decrease in  FVC and FEV1 , it could be obstructive 
or restrictive but  the distinction will depend  on the absolute FEV1/FVC 
ratio. If  ratio is normal or increased, a restrictive defect  may be present. 
However, to confirm  restrictive lung disease, the patient should assessed 
with respect to his lung volumes. If the TLC is<80%, the pattern is 
restrictive. 
 A reduced FEV1 and absolute FEV1/FVC ratio suggests an 
obstructive ventilatory pattern. The mid-expiratory flow rate (FEF 25–75%) 
is the average forced expiratory flow rate recorded over the middle 50 % 
of the FVC. It helps in diagnosing an obstructive ventilatory 
pattern.usually  the  reduction in FEF 25–75% of  <60 % of  the predicted 
and low to normal FEV1/FVC ratio may confirm airway obstruction
45
.                                               
 The final step in interpretation  is to determine if any additional 
 52 
testing is necessary to further define the detected abnormality by 
spirometry. Static lung volume measurement is required to make a 
definitive diagnosis of restrictive type of lung disorder. 
Figure 13. showing flow chart to interpret  spirometric values 
 
 
 
 
 
 
 
 53 
HISTORICAL REVIEW ON WORKS RELATED  TO PFT  IN 
TYPE 2 DM 
 P.Lang et al documented the possible associations between 
Diabetes mellitus, plasma glucose and the spirometric values like FVC & 
FEV1. They did a cross sectional study covering about 11,763 subjects of 
Copenhagen city.  It showed slight impairement in lung function which 
was more prominent in diabetic subjects, who were taking insulin than 
those taking oral hypoglycaemic agents. They finally concluded saying 
that both  
 IDDM & NIDDM were having reduced lung functions since they 
had decreased FVC & FEV1.
46 
 There are many studies which have reported decreased pulmonary 
capacity in DM patients due to changes in elastic properties of 
lungs.
47,48,49,50 
 Walter.E.Robert et al showed the association between state of 
glycaemia and the pulmonary functions. It included  87 members of 
Framingham and the result was reduction in FVC, FEV1 & FEV1/FVC 
ratio.
51 
 54 
 Davis.A.Wendy et al studied and explained about the concept of 
reduced pulmonary function test in Type 2 DM in association with their 
glycemic exposure. This study included 495 patients with Type 2 DM and 
were studied between 1993 to 1994 by cohort study and 125 were 
restudied after 7 years. They found a decrease in mean % predicted 
values and annual decline of FVC, FEV1, PEF and Vital capacity.
52
       
 Is lung a “target organ” in diabetes mellitus was popular study 
carried  out by Malcolm Sander. There is evidence of lung involvement in 
diabetic patients which is histopathologically proven ie.., by the process 
of alveolar epithelial thickening and thickening in the basal lamina of 
pulmonary capillaries highly suggesting the phenomenon of pulmonary 
microangiopathy. Probably the alteration in lung tissue is due to the non-
enzymatic glycosylation, which thereby causes decreased elastic recoiling 
of lung tissues. These changes finally leading to reduced lung volumes in 
diabetes mellitus.
53 
 Another study carried out by Davis Timothy M.E et al on 
pulmonary functions in Type 2 DM covering about 421 patients. It 
showed reduction in the means of spirometric measurements by 9.5%. 
They also showed that there was no correlation between HbA1c and 
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spirometric measures, but there was a correlation with respect to duration 
of diabetes mellitus.
54 
 Sreeja C.K et al studied lung function on 20 subjects with Type 2 
DM, 20 with Type 1 DM and 40 control subjects. It showed significant 
reduction in FEV1/FVC, total lung capacity and lung volumes in both 
diabetic groups compared to control. They also suggested alteration in 
collagen tissue of lungs & loss its of recoiling capacity.
55 
 
Mohan kumar et al studied on pulmonary complications in 
diabetics of elderly age group. Total lung capacity, lung volume and 
compliance of lung are decreased. Diffusion capacity of carbon monoxide 
was also reduced in them. They attributed the presence of increased non-
enzymatic glycosylation which interferes with connective tissue cross 
linkages
56
.  
 Dharwadkar AR et al studied 40 type 2 DM patients with age 
above 30 years and duration of 1 to 20 years. He showed reduction in 
lung parameters like FEV1, FEV1% and demonstrated negative 
correlation with respect to glycemic status
57 
 A study by A.S Agarwal et al in 2010 exhibited decrease in 
diffusion capacity in Type 2 DM patients.
58 
 56 
 Hsin-chieh et al did a cross sectional study in diabetic patients & 
prospectively analysed the association with declining lung functions. The 
diabetic group showed significant reduction in FVC and FEV1.
59 
 There are also reports which suggest there is no correlation 
between lung functions and the presence of microvascular complications 
or the status of glycaemic control. 
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MATERIALS AND METHODOLOGY 
 45 Type 2DM  patients were selected for this study of age more 
than 35 years and with duration of diabetes > 5 years. These patients were 
selected from  Dr.Ambedkar  Institute Of  Diabetology, KMCH (kilpauk 
medical college hospital ) who were getting treated as out patients. 45 
healthy volunteers were assigned as control group, most of them being 
staffs of  kilpauk medical college hospital.   
 This study was a randomised  case control study carried out from 
January 2011  to December 2011,in collaboration with departments of  
Diabetology, Respiratory medicine, & Department of ophthalmology.  
The exclusion criterias were  Smokers, history of hypertension, obesity, 
previous history of lung disease   (COPD, PTB, PT SEQULAE ), 
Subjects with signs & symptoms of respiratory infection at the time of 
test, Subjects having history of admission for respiratory illness during 
past 6months & Subjects with cardiovascular illness. 
 The study was carried out after explaining the procedure & taking a 
written informed consent from the patients and volunteers. 
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DESCRIPTION OF THE DEVICE : 
 “SPIROLAB” is a new generation spirometer. It facilitates the total 
valuation of lung functions. This apparatus can measure FVC(forced  
vital capacity), VC(slow vital capacity), MVV(maximum voluntary 
ventilation test) and breathing pattern tests and calculates an index of test 
acceptability and a measure of reproducibility , and also gives functional 
interpretation following the latest American thoracic society 
classification. 
Figure 14  showing  SPIROMETER: 
 
 
Display 
 
 
Flow sensor 
Mouth piece 
Key board 
Flow sensor 
compartment 
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 This apparatus is supplied with an RS-232 opto-isolated serial 
communication port. The core of  the system is a flow meter which is a 
bi-directional digital turbine flow meter which is connected through the 
serial port RS-232 to a data elaboration device that use electronic and 
mechanical procession components. 
 The spirometric parameters are measured and displayed after each 
test. The flow/volume curve is shown in real time. Each time can be 
repeated several times. The  best parameters  are used for interpretation. 
After each test session, the results are compared to the relevant predicted 
values and the percentage ratio between measured and predicted is shown 
for each parameter. The predicted values are selected as recommended by 
ERS (European Respiratory Society). 
 % predicted = measured/predicted × 100 
 The test can be repeated more than once and the best result is 
memorized in order to recall it from the spirometer’s  memory. The best 
test is determined following the ATS(American Thoracic Society) and 
ERS(European Respiratory Society) standards.           
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MEASURING  HbA1c :  
 HbA1c is a measure of the quantity of glucose which is attached to 
the haemoglobin present in red blood cells. The higher the A1c, the 
higher was the blood glucose levels over the last two to three months. 
HbA1c  was measured for the study group using  “BIO-RAD”  method. 
MEASURING  FOR  MICROALBUMINURIA : 
 Microalbuminuria was measured in a spot urine sample collected 
from the patient. The interpretation  about the presence was made on 
basis of  ADA recommendations. The method used was 
NEPHALOMETRY. 
NORMAL < 30 mg/g creatinine 
MICROALBUMINURIA 30-299 mg/g creatinine 
NEPHROPATHY >300 mg/g creatinine 
 
STATISCAL ANALYSIS: The SPSS software was used to analyse the 
obtained datas statistically. Various tests and methods were implemented 
to analyse such as student ‘t’ test , pearson’s correlation coefficient test 
etc. Microsoft excel and word were used to compute the details. 
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SELECTION OF  GROUPS :  
 The diabetics were selected from diabetology out patient clinic. All 
were of age more than 35 years and with more than 5 years duration of 
diabetes.  An elaborate  medical history was obtained through a 
questionnaire which covered patients general details, smoking history, 
family history, treatment history  to rule out the exclusion criterias. 
Height, weight and BMI, waist circumference was recorded. They were 
screened for hypertension  as per JNC 7 blood pressure guidelines
JNC 7
. 
Blood sample for measuring  FBS,  ECG  to rule out ischaemic heart 
disease, chest xray to rule out COPD and other respiratory illness like 
tuberculosis (new or old) were taken. Volunteers for the control group 
were selected in the same above said way. 
BMI:   
 BMI was calculated as  weight( in kgs ) / height 
2 
(in meters). 
BMI>30 were excluded from the study. 
BLOOD PRESSURE : 
 Blood pressure was measured for the groups using a mercury 
sphygmomanometer in right upper limb in supine supine position. For the  
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diabetic group, the measurement in standing position was also made to 
find out  postural hypotension.  
WAIST CIRCUMFERENCE : 
 The waist circumference was measured from the midpoint between 
the  lower ribs measured at the sides and the iliac crest. This was done 
using a measuring tape. 
PROCEDURE OF LUNG FUNCTION TESTING :  
 The procedure of spirometry test was demonstrated to both the 
groups and the test was done for them after obtaining written consent 
from them.  The test was done using a  RS 232-C spirometer. It was 
repeated 3 times at an interval of 15 minutes. The following values were 
recorded: 
 FVC 
 FEV1 
 FEV1/FVC 
 PEF 
 FEF 25%-75% 
 Printouts of the recorded values were taken from the spirometer for 
analysis.  
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PROCEDURE : 
Figure 15. showing how spirometry  is done  
 
 The best of 3 values were taken and interpretation was made. 
 After 2 hours, blood sample was taken for measuring PPBS and 
HbA1c  levels. Urine was tested for the diabetic group for the  presence 
of albumin. The diabetic patients were shown to an expert 
ophthalmologist in KMCH to check for the presence of diabetic 
retinopathy. 
 The details of all the 45 diabetics and 45 controls were tabulated as 
master charts. Statistical treatment was given by the following:  
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1. Student ‘t’ test which was used to find out the significant 
difference of pulmonary functions between the study and control 
group.  
 
2. Pearsons correlation coefficient60 was made use to find out the 
correlation of spirometric values with respect to duration of 
diabetes, FBS, PPBS, HbA1c. 
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RESULTS AND ANALYSIS 
 Spirometry  was done in 45 Type 2 DM patients & 45 healthy 
volunteers. The aim was to find out the effect of diabetes mellitus on lung  
functions. 
 The basis characters of both the groups are shown in Table. 6. The 
results of the spirometry test for both the groups are shown in Table- & 
Table-. Rearrangements of the master charts were done according to the 
requirements to find out the relationship of variables like duration of DM, 
FBS, PPBS, HbA1c on the pulmonary functions. 
 Student ‘t’test was used to analyse the statistical difference of the 
spirometric values between the 2 groups.  
 Pearson’s correlation coefficient test was used to find out the 
statistical correlation of spirometric values with duration of  DM, FBS, 
PPBS, HbA1c . 
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Table 5. showing sex distribution in case & control groups 
Group Sex Frequency % 
Case 
Male 15 33.3 
Female 30 66.7 
Control 
Male 15 33.3 
Female 30 66.7 
 
 
 
 Both the groups ( CASE & CONTROL ) had 15 males and 30 
females. They were of age more than 35 years with a BMI of less than 30. 
 
 
 
Male 
Female 
Male 
Female 
CASE CONTROL 
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Table 6. showing comparison  of spirometric values of the 2 groups 
Parameters 
Case Control 'p' value 
Mean Range SD Mean Range SD 
FVC 2.09 
1.41-
3.21 0.55 2.8 
1.72-
3.93 0.63 
0.000 
FEV1 1.87 
0.95-
3.33 0.54 2.6 
1.67-
5.35 0.7 
0.000 
FEV1/FVC 87.38 
50.3-
96.1 7.16 90.58 
77.9-
94.1 2.77 
0.006 
PEF 3.96 1.6-7.81 1.6 5.1 
2.43-
8.34 1.76 
0.002 
FEF  
25-75% 2.41 
1.03-
5.62 1.04 3.63 
1.94-
5.36 1.02 
0.000 
 
Impact of Type 2DM on Pulmonary functions 
 The impact of  Type 2DM on pulmonary functions is shown in 
Table. 6. The statistically significant difference was made out between 
the 2 groups using student ‘t’ test.  
 68 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
FVC FEV1 FEV1/FVC PEF FEF 25-75% 
Case 
Control 
Graph 1.showing difference in spirometric values between 2 groups 
 
 
 
 
 
 
 
 
 
Type 2DM and FVC : 
 Table - & graph – reveals that the FVC in Type 2 DM is decreased 
when compared to the control group. Type 2 DM patients having a mean 
at 2.09±0.55  with a range of 1.41-3.21 compared to controls having a 
mean of 2.80±0.63 with a range of 1.72-3.93.  
 This result favours the concept of  Davis M.E Timothy et al’s study 
which showed that FVC in diabetics is decreased by 9.5%. 
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Type 2DM and FEV1 : 
 Table - & graph – reveals that the FEV1 in Type 2 DM is 
decreased when compared to the control group. Type 2 DM patients  had 
a mean at 1.87±0.54  with a range of 0.95-3.33  compared to controls 
having a mean of 2.60±0.70 with a range of 1.67-5.35.  
 This result also favours the concept of Timothy’s study who 
showed an average of 9.5% decrement of FEV1 in diabetic patients. 
Type 2 DM and FEV1/FVC : 
 Table - & graph- shows that there is little difference in FEV1/FVC 
in the form of decrement when compared to the controls, which is of 
statistical significance. 
 Type 2 DM patients  had a mean at 87.38±7.16  with a range of  
50.3-96.1  compared to controls having a mean of  90.58±2.77  with a 
range of  77.9-94.1.  
Type 2 DM and PEF :  
 Table - & graph – reveals that the  PEF  in Type 2 DM is decreased 
when compared to the control group. Type 2 DM patients having a mean 
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at 3.96±1.60  with a range of 1.6-7.81 compared to controls having a 
mean of  5.10±1.76 with a range of  2.43-8.34.  
Type 2 DM and FEF 25-75% :  
 Table - & graph – reveals that the  FEF25-75%  in Type 2 DM is 
decreased when compared to the control group. Type 2 DM patients 
having a mean at 2.41±1.04 with a range of  1.03-5.62 compared to 
controls having a mean of  3.63±1.02 with a range of  1.94-5.36.  
Table 7. showing  the difference in % prediction between 2 groups 
Parameters Group Mean S.D 'p' value 
FVC% 
Case 84.84 17.05 0.000 
Control 95.87 9.47 
FEV1% 
Case 90.24 16.62 0.000 
Control 102.91 10.63 
FEV1/FVC% 
Case 110.69 8.87 0.034 
Control 113.8 3.89 
PEF% 
Case 58.96 18.43 0.001 
Control 70.76 13.72 
FEF 25-75% 
Case 71.64 23.11 0.000 
Control 101.67 19.87 
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Type 2 DM and FVC% 
 FVC%  is decreased in diabetic group when compared to the 
controls. The mean in diabetic group being 84.84±17.05 when compared 
to 95.87±9.47 in control group. 
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Type 2 DM and FEV1% 
 FEV1%  is decreased in diabetic group when compared to the 
controls. The mean in diabetic group being  90.24±16.62 when compared 
102.91±10.63  in control group. 
Type 2 DM and FEV1/FVC% 
 FEV1/FVC%  is decreased in diabetic group when compared to 
the controls. The mean in diabetic group being  110.69 ±8.87 when 
compared to 113.80 ±3.89 in control group. 
Type 2 DM and PEF% 
 PEF%  is decreased in diabetic group when compared to the 
controls. The mean in diabetic group being 58.96 ±18.43 when compared 
to70.76 ±13.72 in control group. 
Type 2 DM and FEF 25-75% 
 FEF 25-75%  is decreased in diabetic group when compared to 
the controls. The mean in diabetic group being 71.64 ±23.11 when 
compared to 101.67 ±19.87 in control group. 
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Table 8. DISTRIBUTION OF SPIROMETRIC  
PATTERN IN TYPE 2 DM 
Spirometric 
pattern 
 Case Control 
Normal 
Count 25 45 
% within 
interpretation 
35.70% 64.30% 
Mild restriction 
Count 14 0 
% within 
interpretation 
100% 0 
Moderate 
restriction 
Count 6 0 
% within 
interpretation 
100% 0 
 
Graph 3. showing pattern of lung function in diabetic group 
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 31% of the diabetics had mild restriction of pulmonary  functions 
 13% of the diabetics had moderate restriction  of pulmonary 
 functions. 
 These collectively had long duration of  DM  compared to rest  of 
the diabetics who underwent spirometry test. 
TABLE 9. CORRELATION OF PFT VALUES WITH  
DURATION OF DIABETES 
 
FVC 
FVC-R -0.280 
FVC% -0.445** 
FEV1 
FEV1-R -0.259 
FEV1% -0.498** 
FEV1/FVC 
FEV1/FVC-R -0.253 
FEV1/FVC% -0.209 
PEF 
PEF-R -0.296* 
PEF% -0.471** 
FEF 25-75% 
FEF 25-75%-R  -0.297* 
FEF 25-75%(%)  -0.461** 
 
                            **. Correlation is significant at the 0.01 level (2-tailed). 
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FVC & Duration of  Diabetes 
 FVC-R  has a weak  negative correlation with respect to 
duration of diabetes. FVC%  has more strong negative correlation with 
respect to duration of diabetes, which is more significant, ie.., FVC 
decreases with increasing duration of diabetes. 
FEV1 & Duration of  Diabetes 
 FEV1-R  has a weak  negative correlation with respect to 
duration of diabetes. FEV1 %  has more strong negative correlation with 
respect to duration of diabetes, which is more significant, ie.., FEV1  
decreases with increasing duration of diabetes 
FEV1/FVC & Duration of  Diabetes 
 FEV1/FVC-R  has a weak  negative correlation with respect to 
duration of diabetes ie..,FEV1/ FVC decreases with increasing duration of 
diabetes. FEV1/ FVC%  also has a weak negative correlation with respect 
to duration of diabetes. 
PEF & Duration of  Diabetes 
 PEF-R  has a moderate  negative correlation with respect to 
duration of diabetes ie.., PEF decreases with increasing duration of 
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diabetes. PEF%  has more strong negative correlation with respect to 
duration of diabetes, which is more significant. 
FEF 25-75% & Duration of  Diabetes 
 FEF 25-75%-R  has a moderate  negative correlation with 
respect to duration of diabetes ie.., FEF 25-75% decreases with increasing 
duration of diabetes.     
 (FEF 25-75%) %  has more strong negative correlation with 
respect to duration of diabetes, which is more significant. 
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Table 10. CORRELATION OF FBS WITH PFT VARIABLES 
FVC 
FVC-R -0.49** 
FVC% -0.691** 
FEV1 
FEV1-R -0.271 
FEV1% -0.477** 
FEV1/FVC 
FEV1/FVC-R -0.088 
FEV1/FVC% -0.087 
PEF 
PEF-R -0.287 
PEF% -0.58** 
FEF 25-75% 
FEF 25-75%-R -0.525** 
FEF 25-75%(%) -0.644** 
 
                        **. Correlation is significant at the 0.01 level (2-tailed). 
Effect of FBS on FVC 
 Both FVC & FVC%  have a strong negative correlation with 
fasting blood sugar values, ie.., FVC & FVC% decreases as the FBS 
increases. 
Effect of FBS on FEV1 
 FEV1 has a weak negative correlation than the  FEV1%  which 
has a strong negative  correlation, ie., FEV1 & FEV1%  decreases as FBS 
value increases. 
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Effect of FBS on FEV1/FVC 
 Both  FEV1/FVC & FEV1/FVC%  have  no significant 
relationship with respect to the FBS values. 
Effect of FBS on PEF 
 PEF has a weak negative correlation than the  PEF%  which 
has a strong negative  correlation, ie., PEF%  decreases as FBS value 
increases. 
Effect of FBS on FEF25-75% 
 Both FEF 25-75% &( FEF 25-75%) %  have a strong negative 
correlation with fasting blood sugar values, ie.., FVC & FVC% decreases 
as the FBS increases. 
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Table 11. CORRELATION OF PPBS WITH PFT VARIABLES 
FVC 
FVC-R -0.548** 
FVC% -0.742** 
FEV1 
FEV1-R -0.319* 
FEV1% -0.527** 
FEV1/FVC 
FEV1/FVC-R -0.093 
FEV1/FVC% -0.088 
PEF 
PEF-R -0.307* 
PEF% -0.577** 
FEF 25-75% 
FEF 25-75%-R -0.606** 
FEF 25-75%(%) -0.713** 
 
             **. Correlation is significant at the 0.01 level (2-tailed). 
Effect of PPBS on FVC 
 Both  FVC & FVC%  have a strong negative correlation with 
fasting blood sugar values, ie.., FVC & FVC% decreases as the PPBS 
increases. 
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Effect of PPBS on FEV1 
 FEV1 has a moderate negative correlation than the  FEV1%  
which has a strong negative  correlation, ie., FEV1 & FEV1%  decreases 
as PPBS value increases. 
Effect of PPBS on FEV1/FVC 
 Both  FEV1/FVC & FEV1/FVC%  have  no significant 
relationship with respect to the PPBS values. 
Effect of PPBS on PEF 
 PEF has a moderate negative correlation than the  PEF%  
which has a strong negative  correlation, ie., PEF%  decreases as PPBS 
value increases 
Effect of PPBS on FEF25-75% 
 Both FEF 25-75% &( FEF 25-75%) %  have a strong negative 
correlation with post prandial  blood sugar values, ie.., FVC & FVC% 
decreases as the  PPBS increases. 
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Table 12.CORRELATION OF HbA1c WITH PFT VARIABLES 
FVC 
FVC-R -0.301* 
FVC% -0.45** 
FEV1 
FEV1-R -0.288 
FEV1% -0.483** 
FEV1/FVC 
FEV1/FVC-R -0.211 
FEV1/FVC% -0.191 
PEF 
PEF-R -0.329* 
PEF% -0.515** 
FEF 25-75% 
FEF 25-75%-R -0.339* 
FEF 25-75%(%) -0.453** 
 
             **. Correlation is significant at the 0.01 level (2-tailed). 
Effect of  HbA1c  on FVC 
 FVC has a moderate negative correlation  & FVC%  have a strong 
negative correlation with  HbA1c levels, ie.., FVC & FVC% decreases as 
the HbA1c  increases. 
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Effect of  HbA1c  on FEV1 
 FEV1 has a weak negative correlation than the  FEV1%  which has 
a strong negative  correlation, ie., FEV1 & FEV1%  decreases as HbA1c 
value increases. 
Effect of  HbA1c  on FEV1/FVC 
 FEV1/FVC has a weak negative correlation  & FEV1/FVC%  has  
no significant relationship with respect to the  HbA1c  values. 
Effect of  HbA1c  on PEF 
 PEF has a  moderate negative correlation than the  PEF%  which 
has a strong negative  correlation, ie., PEF%  decreases as  HbA1c  value 
increases 
Effect of  HbA1c  on FEF25-75% 
  FEF 25-75% has a moderate negative correlation &( FEF 25-75%) %  
have a strong negative correlation with HbA1c  values, ie.., FVC & 
FVC% decreases as the  HbA1c increases. 
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Graph 4. showing association of restrictive lung function with other  
diabetic complications 
 
 
 Out of the 20 diabetic patients who had restrictive pattern lung 
function, 10 had diabetic nephropathy & 6 had retinopathy 
changes. 
 9 had family history of diabetes mellitus. 
 19 had history of giddiness, 7 with decreased vision & 5 with 
history of tingling sensation in both lower limbs suggestive of 
peripheral neuropathy. 
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DISCUSSION 
 This study was done to find out the impact of diabetes or the 
pulmonary functions. Two  Groups namely the study & control groups 
were assigned with equal sex distribution along with fulfilment of 
inclusion and exclusion criteria already mentioned.  
 All the Spirometric values namely  FVC, FEV1, FEV1/FVC, PEF,      
FEF 25-75% were having a mean decrease in diabetic group compared to 
the control group which was statistically proven by getting a P value of 
<0.05. 
 The % prediction of the Spirometric parameters also showed a 
decrease in diabetic group compared to the controls.  
 Among the 45 patients in diabetic groups, 14 had mild restrictive 
and 6 of their had moderate Spirometric pattern when analysed 
individually.  
EFFECT OF DURATION OF DM-2 ON  PULMONARY 
FUNCTIONS: 
 In the study group, it was found that the FVC%, FEV1%, PEF and 
PEF%, FEF 25-75% was having a strong negative correlation with the 
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duration of DM-2. ie., they tend to decrease with respect to increase in 
duration of DM-2.  FEV1/FVC had only a weak negative correlation with 
the duration of DM-2  
 This Outcome was in favourable with the concept of Davis 
Timothy et al’s study. They too showed a negative correlation of 
Spirometric values with the duration of Diabetes.  
EFFECT OF FBS ON PULMONARY FUNCTION:  
 This study showed a strong negative correlation of FVC & %, 
FEV1%, PEF%, FEF 25-75% & its % with respect to FBS values, ie., 
these parameters tend to decrease with respect to increase in FBS values. 
But, the FEV1/FVC did not show any significant correlation.  
EFFECT OF PPBS ON PULMONAY FUNCTION: 
 This study showed a strong negative correlation of FVC & %, 
FEV1%, PEF%, FEF 25-75% & % with respect to the PPBS values, ie., 
they tend to decrease with respect to increase in PPBS values. But, the 
FEV1/FVC did not show any significant correlation with respect to FBS 
values.  
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 This was similar to the results of “P.Lang et al” study who showed 
negative correlation of spirometric values with respect of Spirometric 
values with respect to the glycemic status.  
EFFECT OF HbA1c ON PULMONARY FUNCTION: 
 This study showed a strong negative correlation of FVC%, 
FEV1%, PEF% and FEF 25-75% with respect to the HbA1c level.  ie., 
They tend to decrease with respect to increase in HbA1c levels which 
means that the Spirometric parameters decrease more in the poorly 
controlled diabetes patients.  
 5 out of 45 in the diabetic group were having mild NPDR, and they 
showed also mild restriction pattern in spirometry. 1 had PDR in fundus 
and moderate restriction in spirometry. 
 There results give us a clear idea that there is a  prevalence of 
restrictive pattern of lung function  in the diabetic population. Also that 
the Spirometric parameters are negatively correlated with respect to 
increase in FBS, PPBS, HbA1c values and also with respect to the 
duration of Diabetes Mellitus.  
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 Out of the 20 diabetic patients who had restrictive pattern lung 
function, 10 had  diabetic nephropathy & 6 had retinopathy changes. 
Which suggested the presence of microvascular complications.  
 The prevalence of restriction pattern of lung functions in diabetic 
population which is indicative of microvascular complication, makes us 
more cautious regarding tight control of glycemic status.  Since this 
restriction pattern will add to the morbidity and thereby increasing the 
early mortality rate in diabetic patients. 
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CONCLUSION 
1. The spirometric parameters in general  were consistently lower in 
the diabetic group compared to the non diabetic group. 
2. All the 5 parameters ie.., FVC, FEV1, FEV1/FVC, PEF, FEF 25-75%  
which were planned for the comparison showed statistically 
significant difference in form of decrement in diabetic group 
compared to the non-diabetics. 
3. The pattern of  spirometric parameters in diabetic group suggested 
the prevelance of restriction pattern in lung functions, which can be 
attributed to the non-enzymatic glycosylation of connective tissue 
resulting in the same 
4. Patients with diabetic retinopathy invariably had restriction pattern 
in spirometry. 
5. All these points to a conclusion that DIABETES MELLITUS 
causes decrement in lung functions in the form of restriction which 
is more seen in patients with longer duration of  DM & patients 
with uncontrolled glycemic status.  
6. This study adds to the literature insisting the prevalence of  
restriction pattern  of lung function in diabetics, and hence 
suggesting more extensive works on this field. Probably adding 
diffusion  studies to this can result in more clear idea of the 
concepts. 
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LIMITATIONS AND RECOMMENDATIONS 
1. The study population was too small, it needs a bigger population 
and extensive datas to define the significant difference in a more 
accurate way. 
 
2. Smoking and hypertension were the exclusion criterias., so it was 
difficult to collect male diabetics who were non smokers and 
without hypertension. Smoking was ruled out based on patients 
history, and there is a question of  reliability. 
 
3. Cardiac disease was ruled out on the basis of history and 
electrocardiogram. Echocardiogram was not done for the diabetics, 
so silent ischaemia in diabetics was not ruled out confidently.  
 
4. There may be  other confounding factors too which could have 
affected the result of this tudy, since patients were selected only 
based on a simple history taking and clinical examination. 
 
5. This study did not included diffusion capacity assessment, which 
can give more explanation towards the restriction pattern  in 
spirometry in the diabetics. 
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LIST OF ABBREVIATIONS 
IDDM Insulin dependent diabetes mellitus 
NIDDM Non insulin dependent diabetes mellitus 
FBS Fasting blood sugar 
PPBS Post prandial blood sugar 
AGE Advanced glycated end products 
HbA1c Glycated haemoglobin 
ACTH Adreno cortico tropic hormone  
NPDR Non proliferative diabetic retinopathy 
PDR Proliferative diabetic retinopathy 
ESRD End stage renal disease 
CIDP Chronic inflammatory demyelinating polyneuropathy 
TLC Total lung capacity 
FVC Forced vital capacity 
FEV1 Forced expiratory volume in 1
st
 second 
FEF 25-75% Forced expiratory flow during middle one half of FVC 
PEF Peak expiratory flow rate 
ADA American diabetes association 
JNC-7 Joint national committee-7(for Hypertension) 
BMI Body mass index 
DKA Diabetic keto-acidosis 
DCCT Diabetes Control & Complication Trial 
UKPDS United Kingdom Prospective Diabetes study 
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PROFORMA 
 
NAME: 
AGE/SEX: 
OCCUPATION: 
ADDRESS 
 
DURATION OF DIABETES: 
FAMILY H/O COPD: 
TREATMENT HISTORY: 1.OHA 
     2.INSULIN 
                                 3.OHA+INSULIN 
GENERAL EXAMINATION:                                                                                       
P/Ict/Cy/Cl/LN/PE 
HEIGHT:    WEIGHT: 
BMI: 
WAIST CIRCUMFERENCE: 
PULSE: 
BLOOD PRESSURE-----      SUPINE: 
                                       STANDING: 
 
Cardiovascular system                       Abdominal system 
 
 
         DIABETIC RELATED HISTORY 
DECREASED VISION  
TINGLING/NUMBNESS  
BLURRING OF VISION  
GIDDINESS/BLACKOUTS  
INCREASED SWEATING  
INCONTINENCE OF 
URINE/FAECES 
 
TRANSIENT LOC  
FAMILY H/O DIABETES  
PHYSICAL EXERCISE  
 
 
 
 100 
Respiratory system                                  Central nervous system 
 
INVESTIGATIONS 
 
FBS:                                  FUNDOSCOPY: 
PPBS: 
HbA1C: 
B.UREA: 
S.CREATININE: 
U.MICROALBUMIN: 
ECG: 
CHEST X-RAY: 
 
                        PULMONARY FUNCTION TEST                                                                        
PARAMETERS MEASURED PREDICTED 
 
FVC 
 
  
 
FEV1 
  
 
FEV1/FVC 
  
 
PEFR 
  
 
FEF 25%-75% 
  
 
Sl no Name Age Sex   Ht  (mts)
   Wt
(kgs) BMI
waist
circumference
FBS
mg/dl
PPBS
mg/dl
1 bagavaan 36 M 1.72 63 21.29 88 78 136
2 ramesan 37 M 1.68 78 27.63 90 88 122
3 gopalakrishnan 38 M 1.71 72 24.62 85 76 129
4 moorthy 39 M 1.7 69 23.87 84 90 134
5 ganesh 40 M 1.72 72 24.33 76 96 138
6 dananjeyan 38 M 1.74 76 25.1 86 79 118
7 murugan 41 M 1.65 67 24.6 86 88 130
8 balasubramani 40 M 1.65 80 29.38 90 100 124
9 gopinath 42 M 1.66 70 25.4 84 98 120
10 palanivel 39 M 1.57 72 29.21 90 101 124
11 natesan 45 M 1.73 72 24.05 85 105 126
12 jayaram 46 M 1.73 63 21.04 80 95 132
13 prasath 49 M 1.75 80 26.12 83 97 130
14 ayyasamy 52 M 1.67 58 20.79 78 98 120
15 ramanujam 51 M 1.55 57 23.72 85 74 122
16 sakthi 53 F 1.64 58 21.56 86 80 126
17 Pandi 52 F 1.63 58 21.82 81 88 133
18 Sarasu 53 F 1.7 80 27.68 85 85 122
19 Ramayee 50 F 1.71 68 23.25 83 96 120
20 Rani.S 53 F 1.62 60 22.86 84 100 130
21 Rosy 51 F 1.65 79 29.01 87 90 116
22 Frabella 52 F 1.66 77 27.94 80 95 112
23 Sumathra 53 F 1.67 74 26.53 81 88 114
24 Prabha 52 F 1.66 68 24.67 82 96 130
25 Sujitha 53 F 1.6 50 19.53 83 94 98
26 Madhavi 52 F 1.65 80 29.38 80 101 133
27 Mythili.M 50 F 1.66 70 25.4 85 93 128
28 Kamala 47 F 1.54 55 23.19 82 88 124
29 Reeshma 48 F 1.52 56 24.23 84 86 126
30 Vidhya 50 F 1.51 54 23.68 84 94 122
31 Suganya 51 F 1.59 67 27.93 82 103 129
32 Abhinaya sundari 52 F 1.57 59 23.93 78 79 120
33 Chellama 53 F 1.51 68 29.82 84 80 132
34 Ruby 53 F 1.58 50 20.02 81 82 135
35 tamilarasi 53 F 1.74 85 28.07 83 88 136
36 geetha 39 F 1.58 48 19.22 81 85 130
37 vasanthi 42 F 1.47 57 21.75 85 96 128
38 kokila 41 F 1.53 53 22.64 82 93 126
39 porkodi 43 F 1.51 67 29.38 85 96 132
40 mythili 43 F 1.67 70 25.09 84 98 131
41 rani 46 F 1.58 57 22.83 86 102 132
42 ushalakshmi 50 F 1.53 56 23.92 86 78 112
43 shanthi 52 F 1.59 67 26.5 84 90 113
44 parimala 53 F 1.52 65 28.13 83 94 112
45 radha 53 F 1.73 80 26.72 85 96 111
Master chart 1. showing basic characteristics in Control
Sl no Name Age Sex
Duration of
DM Ht (mts) Wt (kgs) BMI Waist circum (cm) FBS mg/dl
PPBS
mg/dl
Treatment
History Hb A1c Urine albumin Fundoscopy
1 Rajaram 47 M 9 1.59 58 22.94 84 168 230 OHA 7.3 micro normal
2 willson 47 M 8 1.75 70 22.85 86 207 317 OHA 7.5 nil normal
3 kanagaraj 52 M 11 1.57 60 24.34 97 240 380 OHA 7.2 macro Mild NPDR
4 rangan 74 M 10 1.64 58 21.56 81 181 272 OHA 7.6 micro Mild NPDR
5 murugesan 64 M 12 1.58 63 25.23 96 190 286 OHA 7.7 micro Mild NPDR
6 narayanasami 67 M 20 1.68 60 21.25 86 175 280 OHA 6.8 nil normal
7 kuppan 48 M 7 1.56 60 24.65 88 120 152 OHA 6.9 nil normal
8 vasanthan 60 M 6 1.54 58 24.45 90 112 130 OHA 6.6 nil normal
9 sivakumar 55 M 12 1.58 62 24.83 92 167 268 OHA 7.2 micro normal
10 mani 48 M 6 1.61 63 24.3 88 102 145 OHA 6.5 nil normal
11 kamalakannan 51 M 7 1.72 70 23.66 89 156 189 OHA 7.4 micro normal
12 arumugam 49 M 7 1.74 68 22.46 94 110 130 OHA 6.9 nil normal
13 murugaiya 48 M 7 1.68 67 23.73 91 106 146 OHA 7 nil normal
14 magesan 48 M 6 1.56 60 24.65 86 106 123 OHA 7.1 nil normal
15 ravi 50 M 7 1.72 58 19.6 88 123 150 OHA 6.9 nil normal
16 Rani 55 F 13 1.52 63 27.2 83 188 260 OHA+INSULIN 7.8 macro Mild NPDR
17 jothi 52 F 12 1.61 65 25.07 85 170 268 OHA 6.9 nil normal
18 sharon 47 F 7 1.45 51 24.25 80 198 287 OHA 6.8 nil normal
19 saraswathi 45 F 7 1.55 63 26.22 80 181 280 OHA 6.7 nil normal
20 lutmary 50 F 6 1.5 65 28.88 82 85 130 OHA 6.5 nil normal
21 jayalaxmi 51 F 9 1.58 72 28.84 91 128 180 OHA 6.6 nil normal
22 renuka 47 F 8 1.5 63 28 95 148 200 OHA 7 nil normal
23 rajeshwari 39 F 6 1.51 62 27.19 83 130 206 OHA 7.2 nil normal
24 girija 51 F 6 1.44 49 23.63 81 156 190 OHA 7.1 nil normal
25 vijayalaxmi 48 F 13 1.5 62 27.55 90 182 290 OHA 7.4 nil normal
26 indira 46 F 6 1.47 64 29.61 94 150 196 OHA 7.2 nil normal
27 govindammal 42 F 8 1.49 55 24.77 78 170 228 OHA 7.3 nil normal
28 parasakthi 50 F 12 1.45 58 27.58 88 190 386 OHA+INSULIN 7.2 macro Mild NPDR
29 kalaivani 44 F 9 1.49 61 27.47 91 114 178 OHA 7.1 nil normal
30 padmavathy 68 F 10 1.55 60 24.9 95 106 124 OHA 6.8 nil normal
31 parvathy 51 F 6 1.46 47 22.04 82 99 130 OHA 6.6 nil normal
32 kottiswari 42 F 15 1.53 63 26.91 91 260 320 OHA+INSULIN 8 macro Moderate NPDR
33 rajam 63 F 7 1.47 53 24.52 81 155 187 OHA 7.1 nil normal
34 muniyamma 55 F 7 1.53 62 26.48 93 130 195 OHA 6.8 micro normal
35 hamsa 39 F 6 1.63 77 28.98 95 140 166 OHA 6.9 nil normal
36 siddiqa 63 F 7 1.53 62 26.48 92 129 200 OHA 7.3 nil normal
37 thenmozhi 50 F 12 1.5 55 24.44 85 230 367 OHA 7.1 nil normal
38 sembammal 58 F 9 1.45 50 23.78 86 168 260 OHA 7.2 nil normal
39 malliga 47 F 11 1.52 43 18.61 66 156 248 OHA 7.1 nil normal
40 savithri.s 53 F 8 1.55 60 24.97 98 161 257 OHA 7.2 nil normal
41 kaliamma 52 F 9 1.51 55 24.12 85 192 280 OHA 7.5 micro normal
42 nagapandi 64 F 6 1.51 55 24.12 84 102 135 OHA 6.5 nil normal
43 sarasamma 52 F 8 1.52 57 24.67 87 127 146 OHA 7.1 nil normal
44 logeswari 45 F 7 1.5 55 24.44 85 110 127 OHA 6.5 nil normal
45 balamma 58 F 12 1.52 60 25.96 89 166 230 OHA 8 micro normal
Master chart 2. showing characterestics in Diabetic group
% % % % %
Recorded Predicted Recorded Predicted Recorded Predicted Recorded Predicted Recorded Predicted
1 bagavaan 1703 3.47 4.03 86 3.13 3.36 93 90.2 80.7 112 7.77 9.16 85 4.56 4.49 102 Normal
2 ramesan 1706 3.36 3.81 88 3.07 3.18 97 91.4 80.6 113 7.47 8.87 84 4.45 4.37 104 Normal
3 gopalakrishnan 1711 4.17 3.93 106 3.21 3.27 98 77 80.4 96 8.02 9.02 89 4.9 4.38 112 Normal
4 moorthy 1715 3.94 3.86 102 3.32 3.21 103 84.3 80.2 105 8.23 8.91 92 2.82 4.32 65 Normal
5 ganesh 1723 3.65 3.94 93 3.36 3.26 103 92.1 80 115 8.34 8.99 93 5.36 4.32 124 Normal
6 dananjeyan 1729 3.56 4.08 87 3.31 3.38 98 93 80.4 116 7.91 9.2 86 5.23 4.44 118 Normal
7 murugan 1735 3.61 3.57 101 3.33 2.98 112 92.2 79.8 116 7.54 8.52 88 5.01 4.14 121 Normal
8 balasubramani 1737 3.68 3.58 103 3.36 3 112 91.3 80 114 7.74 8.56 90 4.97 4.18 119 Normal
9 gopinath 1738 3.67 3.59 102 3.38 2.98 113 92.1 79.7 116 6.89 8.54 81 5.24 4.11 127 Normal
10 palanivel 1742 3.41 3.21 106 3.15 2.72 116 92.4 80.2 115 7.29 8.11 90 4.87 4.07 120 Normal
11 natesan 1746 3.59 3.88 93 3.27 3.17 103 91.1 79.1 115 6.72 8.84 76 4.85 4.12 118 Normal
12 jayaram 1750 3.41 3.85 89 3.21 3.15 102 94.1 78.9 119 6.23 8.79 71 5.17 4.08 127 Normal
13 prasath 1753 3.52 3.89 90 3.19 3.14 102 90.6 78.4 116 6.9 8.79 78 4.76 3.99 119 Normal
14 ayyasamy 1760 3.47 3.31 105 3.21 2.7 119 92.5 77.9 119 6.14 8.05 76 4.82 3.67 131 Normal
15 ramanujam 1764 3.66 2.84 129 3.36 2.35 143 91.8 78 118 6.5 7.47 87 5.08 3.51 145 Normal
16 sakthi 1766 2.86 2.6 110 2.58 2.22 116 90.2 79 114 5.2 6.32 82 3.86 3.17 122 Normal
17 pandi 1769 2.94 2.59 114 2.69 2.21 122 91.5 79.2 116 4.92 6.3 78 3.97 3.19 124 Normal
18 sarasu 1785 2.4 2.84 85 2.2 2.43 91 91.7 79 116 3.96 6.65 60 3.33 3.24 103 Normal
19 ramayee 1790 2.74 2.94 93 2.52 2.52 100 92 79.6 116 5.52 6.8 81 4.03 3.35 120 Normal
20 rani.S 1805 2.63 2.53 104 2.42 2.15 113 92 79 116 4.33 6.21 70 3.55 3.14 113 Normal
21 rosy 1807 2.41 2.69 90 2.27 2.3 99 94.2 79.4 119 5.06 6.44 79 3.65 3.25 112 Normal
22 frabella 1811 2.67 2.71 99 2.39 2.31 103 89.5 79.2 113 3.96 6.46 61 3.34 3.22 104 Normal
23 sumathra 1816 2.42 2.72 89 2.19 2.32 94 90.5 79 115 3.66 6.49 56 2.95 3.2 92 Normal
24 prabha 1821 2.59 2.71 96 2.34 2.31 101 90.3 79.2 114 3.52 6.46 54 3.01 3.22 93 Normal
25 sujitha 1826 2.29 2.45 93 2.01 2.08 97 87.8 79 111 2.98 6.1 49 2.49 3.12 80 Normal
26 madhavi 1835 2.44 2.66 92 2.27 2.27 100 93 79.2 117 4.01 6.41 63 3.39 3.21 106 Normal
27 mythili.M 1837 2.34 2.75 85 2.12 2.35 90 90.6 79.6 114 4.68 6.52 72 3 3.29 91 Normal
28 kamala 1839 2.59 2.36 110 2.33 2.01 116 90 80 112 4.22 5.95 71 3.32 3.24 102 Normal
29 reeshma 1842 2.5 2.25 111 2.23 1.91 117 89.2 80 112 3.83 5.81 66 2.78 3.19 87 Normal
30 vidhya 1846 2.03 2.18 93 1.81 1.84 98 89.2 79.6 112 2.71 5.7 48 2.21 3.1 71 Normal
31 suganya 1850 2.3 2.46 93 2.06 2.09 99 89.6 79.4 113 3.07 6.11 50 2.67 3.17 84 Normal
32 abhinaya sundari 1852 2.32 2.36 98 2.08 2 104 89.7 79.2 113 3.26 5.97 55 2.64 3.11 85 Normal
33 chellama 1857 1.98 2.11 94 1.71 1.77 97 86.4 79 109 2.43 5.61 43 1.94 3 65 Normal
34 ruby 1861 2.07 2.38 87 1.88 2.01 94 90.8 79 115 2.89 5.99 48 2.35 3.09 76 Normal
35 tamilarasi 1864 2.61 2.99 87 2.39 2.57 93 91.6 79 116 5.11 6.87 74 3.62 3.29 110 Normal
36 geetha 1869 2.28 2.69 85 2.08 2031 90 91.2 81.7 112 4.64 6.41 72 3.17 3.57 89 Normal
37 vasanthi 1871 2.21 2.2 100 2.04 1.87 109 92.3 81.1 114 4.13 5.72 72 2.99 3.33 90 Normal
38 kokila 1873 2.21 2.45 90 1.93 2.11 91 87.3 81.3 107 3.06 6.08 50 2.25 3.44 65 Normal
39 porkodi 1876 2.29 2.33 98 2.1 1.99 106 91.7 80.9 113 4.14 5.91 70 2.79 3.34 84 Normal
40 mythili.M 1879 2.57 2.95 87 5.35 2.54 93 91.4 80.9 113 4.19 6.79 62 3.38 3.54 95 Normal
41 rani 1880 2.21 2.53 87 2.03 2.17 94 91.9 80.4 114 4.29 6.2 69 3.07 3.33 92 Normal
42 ushalakshmi 1886 2.07 2.25 92 1.87 1.91 98 90.3 79.6 113 3.62 5.81 62 2.52 3.13 81 Normal
43 shanthi 1889 2.15 2.44 88 1.94 2.07 94 90.2 79.2 114 3.62 6.08 60 2.76 3.14 88 Normal
44 parimala 1894 1.83 2.14 86 1.67 1.81 92 91.3 79 116 3.68 5.66 65 2.41 3.02 80 Normal
45 radha 1901 2.89 2.95 98 2.67 2.53 106 92.4 79 117 5.19 6.82 76 3.91 3.28 119 Normal
Interpretation
FVC FEV1 FEV1/FVC PEF FEF 25-75%
Sl No Name
Spirometer
ID
Master chart 3. showing spirometry results in control group
  
Sl.no name
Famiy h/o
Diabetes
blurring of
vision
giddiness/
blackout
tingling/
numbness
inreased
sweating transient LOC
Physical
exercise
Family h/o
COPD
1 rajaram NO YES YES NO NO NO NO NO
2 willson NO NO YES NO NO NO NO NO
3 kanagaraj NO YES YES YES NO NO NO NO
4 rangan NO NO YES NO NO NO NO NO
5 murugesan YES NO YES NO NO NO NO NO
6 narayanasami YES NO YES NO NO NO NO NO
7 kuppan NO NO NO NO NO NO YES NO
8 vasanthan NO NO NO NO NO NO YES NO
9 sivakumar NO YES YES NO NO NO NO YES
10 mani YES NO NO NO NO NO YES NO
11 kamalakannan YES NO YES NO NO NO NO NO
12 arumugam YES NO YES NO NO NO YES NO
13 murugaiya NO NO NO NO NO NO YES NO
14 magesan YES YES YES NO NO NO YES NO
15 ravi YES NO YES NO NO NO YES NO
16 rani YES NO YES YES YES NO NO YES
17 jothi YES NO YES NO NO NO YES NO
18 sharon YES NO YES NO NO NO NO NO
19 saraswathi YES NO YES NO NO NO YES NO
20 lutmary YES NO NO NO NO NO YES NO
21 jayalaxmi YES YES YES NO NO NO NO NO
22 renuka YES NO NO NO NO NO NO NO
23 rajeswari NO NO NO NO NO NO NO NO
24 girija YES NO YES NO NO NO NO NO
25 vijayalaxmi NO NO YES NO NO NO NO NO
26 indira YES NO YES NO NO NO YES NO
27 govindammal YES NO YES NO NO NO YES NO
28 parasakthi YES YES YES YES YES NO NO NO
29 kalaivani YES NO YES NO NO NO YES NO
30 padmavathy YES NO YES NO NO NO NO NO
31 parvathy NO NO NO NO NO NO YES NO
32 kottiswari YES YES YES YES YES NO NO NO
33 rajam YES NO YES NO NO NO NO NO
34 muniyamma YES NO YES NO NO NO YES NO
35 hamsa NO YES YES NO NO NO NO NO
36 siddiqa YES NO YES NO NO NO YES NO
37 thenmozhi NO YES YES NO NO NO NO NO
38 sembammal NO NO NO NO NO NO NO NO
39 malliga YES NO YES NO NO NO YES NO
40 savithri.s NO NO YES NO NO NO NO NO
41 kaliamma YES NO YES NO NO NO NO NO
42 nagapandi YES NO NO NO NO NO YES NO
43 sarasamma NO NO YES NO NO NO NO NO
44 logeswari YES NO NO NO NO NO YES NO
45 balamma NO YES YES YES NO NO NO NO
 

 
